Hot issues
Our analysis of data from June and July revealed hundreds of pharmaceutical shipments that entered the U.S. from facilities no one would expect, including unregistered Chinese exporters and alternative medicine clinics abroad.
The warning letter was one of about 100 is a new focus on deceptive direct-to-consumer drug advertisements.
The “green list” will help protect patients from unreliable, illegally compounded GLP-1s and simplify screening for border security.
PSM led a coalition of organizations urging leaders of the Senate HELP and House Energy and Commerce committees to help strengthen the FDA’s ability to protect Americans from unsafe and counterfeit medicines and medical products.
A decade ago no one had heard of deadly counterfeit prescription pills. Victims’ families bravely spoke up, lobbied, and rallied for change.
Chinese companies that supplied U.S. compounders have turned to making generic semaglutide for markets where Novo Nordisk’s main patent is expiring in 2026.
Elle published an exposé about bad actors and loose regulation in the medical spa industry.
Our podcast covers the latest in pharma crime and medicine safety.
Like your information on video? Subscribe to our YouTube playlist!
90 countries. 769 arrests. 123 criminal networks. Over 50 million doses of fake medicine.
Learn what FDA found at this compounding facility.
Fake GLP-1 medications are putting lives at risk.
Click the images below to see more recent videos.